title: Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
abstract: OBJECTIVE
  Optimal chemotherapy regimen for peripheral T-cell lymphomas (PTCL) has not been fully defined. This study aimed to evaluate the optimal chemotherapy regimen in the first-line treatment for PTCL patients.
  
  
  METHODS
  Between 2003 and 2014, 93 consecutive patients with PTCL were enrolled in this study. Of 93 patients, 42 patients received CHOPE, 40 patients with CHOP, and 11 patients with GDP regimen.
  
  
  RESULTS
  Response could be evaluated in 88 of 93 patients at the end of primary treatment. The CR rate for patients received CHOP (n = 38), CHOPE (n = 39), and GDP (n = 11) were 28.9, 51.3, and 45.5%, respectively, (P = 0.132) with an ORR of 65.8, 76.9, and 90.9%, respectively, (P = 0.210). The median follow-up time was 17.1 (1.4-108.3) months. Median progression-free survival (PFS) in CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) groups were 6.0, 15.3, and 9.7 months (P = 0.094) with 1-year PFS of 35.0, 54.8, and 45.5%, respectively, (P = 0.078). One-year OS for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) were 65.0, 83.3, and 100%, respectively, (P = 0.013) (CHOP vs CHOPE, P = 0.030; CHOP vs GDP, P = 0.024; CHOPE vs GDP, P = 0.174).
  
  
  CONCLUSIONS
  CHOPE has a trend to improve CR rate, 1-year PFS and OS compared with CHOP alone. GDP shows promising efficacy which worth further exploration in large cohort studies. Clinical experience presented in this study may serve as reference for future large cohort studies.
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Bo
authors.initials: B
authors.lastname: Jia
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Shaoxuan
authors.initials: S
authors.lastname: Hu
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Jianliang
authors.initials: J
authors.lastname: Yang
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Shengyu
authors.initials: S
authors.lastname: Zhou
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Qin
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Lin
authors.initials: L
authors.lastname: Gui
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.affiliation: b Department of Medical Record Library, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Hua
authors.initials: H
authors.lastname: Lin
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Changgong
authors.initials: C
authors.lastname: Zhang
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Puyuan
authors.initials: P
authors.lastname: Xing
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Liqiang
authors.initials: L
authors.lastname: Zhou
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Xiaohui
authors.initials: X
authors.lastname: He
authors.affiliation: a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone; D000093542:Gemcitabine
keywords: CHOPE; Chemotherapy; Gemcitabin; Peripheral T-cell lymphomas